In contrast to CD8+ T cells, metformin inhibited tumor growth, decreased IL-22 production and de novo generation of Th1- and Th17 cells from naïve CD4+ cells in a mouse hepatocellular carcinoma model [76]. This evidence concerns the gene CD4 and neoplasm.